ArticleFrontiers in neurology2017
New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.
Article in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04496830 (Cerebrospinal Fluid-biomarkers-based Diagnostic and Prognostic Models for Multiple Sclerosis), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cerebrospinal Fluid-biomarkers-based Diagnostic and Prognostic Models for Multiple Sclerosis
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer's disease and multiple sclerosis: a systematic review.Frontiers in immunology · 2023Pooled it
- Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis.Frontiers in neurology · 2022Pooled it
- Pooled it
- Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis.The Journal of clinical investigation · 2025Trial
- Trial
- Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity.Multiple sclerosis and related disorders · 2019Trial
- From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.Annals of neurology · 2026Article
- Smartphone postural sway and pronator drift tests as measures of neurological disability.BMC neurology · 2025Article
- Smartphone Postural Sway and Pronator Drift tests as Measures of Neurological Disability.medRxiv : the preprint server for health sciences · 2024Article
- Data-driven risk/benefit estimator for multiple sclerosis therapies.medRxiv : the preprint server for health sciences · 2024Article
- Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.Journal of neurology · 2024Observational
- Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis.Frontiers in immunology · 2024Review
- Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- CNS Ageing in Health and Neurodegenerative Disorders.Journal of clinical medicine · 2023Review
- Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis.Degenerative neurological and neuromuscular disease · 2023Article
- Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review.Frontiers in neurology · 2023Review
- Prospective outcome analysis of multiple sclerosis cases reveals candidate prognostic cerebrospinal fluid markers.PloS one · 2023Article
- Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis.Frontiers in neurology · 2023Article
- Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms.Nature communications · 2022Article
- FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis.BMJ open · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The search for the genetic foundation of multiple sclerosis (MS) severity remains elusive. It is, in fact, controversial whether MS severity is a stable feature that predicts future disability progression. If MS severity is not stable, it is unlikely that genotype decisively determines disability progression. An alternative explanation tested here is that the apparent instability of MS severity is caused by inaccuracies of its current measurement. We applied statistical learning techniques to a 902 patient-years longitudinal cohort of MS patients, divided into training (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.